These 20 women are 2018's Fiercest in the life sciences industry.
Read 2018's Fiercest Women in Life Sciences report!
As part of its $12.5 billion asset swap with Sanofi, BI will cut 327 of its 2,800 workers in France and create 32 new jobs.
Experts urged the U.S. to allow CDC staff to return to the field, though WHO's director-general insists financial and other support should suffice.
As biopharma companies take steps to become more digitally savvy, who should lead the charge? It’s time to identify a digital leadership model.
Merck & Co. boasted some major sales success this year, but the company’s commercial organization will still get a makeover for 2019.
The Chinese API maker at the heart of a global scare and recall of blood pressure medicines has been savaged in an FDA warning letter.
As J&J vies with biosims to big-selling Remicade, prices across the category are falling, an analyst says—and Pfizer's Inflectra has tumbled the most.
J&J CEO Alex Gorsky said Amazon could offer expertise in distribution as well as shake up reimbursement in a potential pharma entry.
GlaxoSmithKline is working to boost its supply of shingles vaccine Shingrix, but in the meantime, a shortage will last until next year.
Connecticut Assistant Attorney General Joseph Nielsen told The Washington Post the generic drug market is possibly the biggest "cartel" in U.S.…
With the help of BioNTech and CEPI's $8.4 million, Imperial College London will work on a self-amplifying RNA vaccine platform.
A Bernstein analyst has previously said that breaking up crop and pharma would be the "best strategy" for Bayer.
